<?xml
version="1.0"
encoding="iso-8859-15"?>
<tokenized>
<doc
id
=
"l2.2.htm">
<title>
norsk
legemiddelhåndbok
l2.2
</title>
<body>
norsk
legemiddelhåndbok
l2.2
l2.2.htm../index.htm
søk
l2.2.htm../t/innhold.htm
l2.2.htminnhold.htm
l2.2.htm../g/innhold.htm
l2.2.htm../div/stikkorda.htm
l2.2.htm../div/hastebehandling.htm
l2.2.html2.2.htm
i41965
l2.2.html2.2.htm
i42006
l2.2.html2.2.htm
i42042
l2.2
midl
motvirk
toksisit
cytostatik
publisert:
20.06.2010
l2.2.1
deksrazoksan
publisert:
20.06.2010
egenskap
deksrazoksan
motvirk
veksthemm
effekt
dna
skad
induser
antracyklin
antracendioner.
deksrazoksan
edt
analog
lett
penetrer
cellemembraner.
intracellulært
hydrolyser
deksrazoksan
adr
925
kraft
kelator
jern
toverd
kationer.
adr
925
kelater
jern
.
fjern
jern
jern
antracyklinkompleks
bind
jern
cell
reduser
derved
dann
ødelegg
reaktiv
oksygenradikaler.
topoisomerase ii
hemm
.
motsetning
antracyklin
induser
kjedebrudd
dna.
farmakokinetikk
deksrazoksan
terminal
eliminasjonshalveringstid
2
x2013
.
9
timer.
ekskresjon
skjer
hovedsak
nyr
.
40
x2013
.
60 %
total
mengd
deksrazoksan
skill
uendr
urinen.
indikasjon
deksrazoksan
bruk
behandling
ekstravasasjon
antracyklin.
vist
beskytt
effekt
deksrazoksan
antracyklininduser
kardiotoksisit
.
verdi
behandling
ennå
klarlagt.
dosering
administrasjon
anbefalt
dos
1000 mg/m
2
kroppsoverflat
intravenøs
infusjon
gitt
1
x2013
.
2
tim
dag
1
2
.
500 mg/m
2
intravenøs
infusjon
gitt
1
x2013
.
2
tim
dag
3.
først
infusjon
start
raskt
mul
6
tim
ekstravasasjon.
infusjon
gis
stor
ven
ekstremit
områd
påvirk
ekstravasasjonen.
bivirkning
van
bivirkning
kvalme/oppk
.
diaré
.
stomatitt
beinmargsdepresjon.
påvirk
leverfunksjon
forhøy
alat/asat
forekomm
også.
samt
bivirkning
raskt
reversible.
gravidit
.
amming
erfaring
bruk
hos
gravid
mangler.
dyreforsøk
vist
teratog
effekt.
bruk
del
cytostatikabehandling
amming
kontrindisert.
forsiktighetsregl
nedsatt
nyrefunksjon
reduser
eliminasjonshast
deksrazoksan
.
bør
pasient
aller
svekk
nyrefunksjon
overvåk
tegn
hematologisk
toksisitet.
kontroll
oppfølging
deksrazoksan
øke
toksisitet
induser
kjemoterapisyklus
pågikk
uhell
skjedd
.
krev
nøye
overvåking
hematologisk
parametre.
informasjon
pasient
bivirkninger.
deksrazoksan
rp.
c
sav
«spepharm»
infusjonssubstan
500 mg.
10
hetteglass:
kr 
101
186
.
60.
kilder.
deksrazoksan
deksrazoksan
.
l2.2.2
mesn
publisert:
20.06.2010
egenskap
mesn
2
x2011
.
merkaptoetansulfonat
sulfhydrylforbind
konsentrer
urin
beskytt
toksisk
virkning
nedr
urinvei
metabolitt
sær
akrolein
cyklofosfamid
ifosfamid.
beskjed
kortvar
beskytt
effekt
nyreskade.
syn
svekk
cytostatisk
effekt
cyklofosfamid/ifosfamid.
farmakokinetikk
mesn
metaboliser
raskt
nest
fullstend
blod
oksydering
inaktiv
metabolitt
.
dimesna.
utskill
.
reabsorber
delvis
nyretubuli
spalt
via
glutation
reduktas
aktiv
mesna.
utskill
hovedsak
via
nyrene.
halveringstid
mesn
ca.
20
minutt
dimesn
1
x2013
.
2
timer.
indikasjon
forebygg
nedr
urinveisskad
ifosfamid
cyklofosfamid.
gis
får
ifosfamid
.
pasient
får
cyklofosfamid
høy
dosering
.
tidliger
fått
cystitt
behandling
cyklofosfamid
dessut
fått
strålebehandling
lill
bekk
hatt
urinveisobstruksjon
tidligere.
dosering
administrasjon
mesn
gis
oftest
i.v.
tilslutning
administrasjon
ifosfamid
høye
dos
cyklofosfamid.
tilfør
hypp
.
f.eks.
ca.
4.
tim
.
gis
ca.
0
.
5
tim
ca.
12
tim
ifosfamid
cyklofosfamid.
total
dos
oft
ca.
60 %
ifosfamiddos
se
spesiallitteratur
.
bivirkning
van
forekommende:
kvalm
.
brekning
.
diaré.
hypotensjon.
hudkløe.
sjeldne:
allergisk
reaksjoner.
gravidit
.
amming
erfaring
bruk
hos
gravid
begrenset.
opplysning
mangl
bruk
amming.
kontraindikasjon
overfølsom
mesn
tiolforbindelser.
mesn
rp.
c
uromitexan
«baxt
oncology»
injeksjonsvæsk
100 mg/ml.
15 
x
4 ml
kr 
163
.
10
.
10 
x
10 ml
kr 
253
.
60.
tablett
400 mg.
10 stk.
enpac
kr 
250
.
00
.
20 stk.
enpac
kr 
467
.
50.
tablett
600 mg.
10 stk.
enpac
kr 
340
.
90
.
20 stk.
enpac
kr 
646
.
70.
l2.2.3
rasburikas
publisert:
20.06.2010
egenskap
rasburikas
enzym
katalyser
omdann
urinsyr
.
produkt
purinnedbrytning
.
allantoin.
allantoin
vannløs
skill
lett
via
nyrene.
tilførsel
rasburikas
dermed
opphopning
urinsyr
risiko
hyperuremisk
komplikasjon
.
sær
nyresvikt
.
unngås
tilstand
stor
nedbrytning
malign
celler.
rasburikas
virk
raskt
gir
vanligvis
normalisering
urinsyrenivå
4
timer.
farmakokinetikk
metaboliser
sannsynligvis
protein
.
f.eks.
peptidhydrolyse.
halveringstid
16
x2013
.
21
timer.
indikasjon
behandling
profylaks
akutt
hyperurikemi
.
forhindr
akutt
nyresvikt
hos
pasient
hematologisk
malignit
høy
tumorbelastning
risiko
rask
nedbrytning
tumorcell
kjemoterapi
startes.
dosering
administrasjon
vanligvis
0
.
2 mg/kg/dag
5
x2013
.
7
dag
.
gitt
intravenøs
infusjon.
se
spesiallitteratur.
bivirkning
allergisk
reaksjon
forekommer.
methemoglobinemi
hemolys
rapporter
.
trol
resultat
h
2
o
2
produser
enzymatisk
omdann
urinsyr
allantoin.
forekomm
sjeld
.
hos
disponer
pasient
g6pd
mangel
.
gravidit
.
amming
opplysning
mangl
bruk
gravidit
amming.
forsiktighetsregl
vær
oppmerksom
mul
allergisk
reaksjon
.
sær
hos
person
atopi.
rasburikas
rp.
c
fasturtec
«sanofi
synthelabo»
injeksjonssubstan
1
.
5 mg.
ampuller:
3 stk.
kr 
2
416
.
90.
kilder.
legemidl
behandling
kreftsykdomm
legemidl
behandling
kreftsykdomm
.
kild
legemidl
behandling
kreftsykdomm
adam
vr
.
legg
m
2007
:
sunitinib
malat
the
treatment
of
metastatic
renal
cell
carcinom
an
gastrointestinal
stromal
tumors.
clin
ther.
29
.
1338
1353.
andersson
bs
.
madd
t
.
tran
ht
.
hu
ww
.
blum
kg
.
chow
ds
.
champlin
re
.
vaughan
wp
2000
:
acut
safety
and
pharmacokinetic
of
intravenous
busulfan
when
used
with
oral
busulfan
and
cyclophosphamid
as
pretransplantation
conditioning
therapy:
a
phas
study.
biol
blood
marrow
transplant.
6
.
548
554.
bareschino
ma
.
schettino
c
.
troiani
t
.
martinelli
e
.
morgillo
f
.
ciardiello
f
2007
:
erlotinib
in
canc
treatment.
ann
oncol.
18
.
vi35
vi41.
beasley
gm
.
ross
.
tyl
ds
2008
:
futur
direction
in
regional
treatment
strategi
melanom
and
sarcoma.
int
j
hypothermi
24
.
301
309.
bennoun
j
.
delord
jp
.
campon
m
.
nguyen
l
2008
:
vinflunine:
a
new
microtubul
inhibitor
agent.
clin
canc
res.
14
.
1625
1632.
berman
e
1992
:
new
drug
in
acut
myelogenous
leukemia:
a
review.
j
clin
pharmacol.
32
.
296
x2013
.
309.
bertino
p
.
piccardi
f
.
port
c.
favoni
r
.
cilli
m
.
mutti
l
.
gaudino
g
2008
:
imatinib
mesylat
enhanc
therapeutic
effect
of
gemcitabin
in
human
malignant
mesotheliom
xenografts.
clin
canc
res.
14
.
541
548.
bues
jm
.
urrechag
e
1991
:
clinical
pharmacokinetic
of
high
dos
dtic.
canc
chemoth
pharmacol.
28
.
475
479.
buie
lw
.
epstein
ss
.
lindley
cm
2007
:
nelarabine:
a
novel
purin
antimetabolit
antineoplastic
agent.
clin
ther.
29
.
1887
1899.
cai
h
.
wang
q
.
luo
j
.
lim
ck
1999
:
study
of
temoporfin
metabolism
by
hplc
and
electrospray
mass
spectrometry.
biomed
chromatogr.
13
.
354
359.
cart
nj
.
keam
sj
2007
:
trabectedin:
a
review
of
its
use
in
the
management
of
soft
tissu
sarcom
and
ovarian
cancer.
drug
67
.
2257
2276.
chang
tk
.
yu
l
.
goldstein
.
waxman
dj
1997
:
identification
of
the
polymorphically
expressed
cyp2c19
and
the
wild
typ
cyp2c9
ile359
allel
as
low
km
catalyst
of
cyclophosphamid
and
ifosfamid
activation.
pharmacogenetic
7
.
211
221.
chattopadhyay
s
.
moran
rg
.
goldman
id
2007
:
pemetrexed:
biomedical
and
cellul
pharmacology
.
mechanism
.
and
clinical
applications.
mol
canc
ther.
6
.
404
417.
chen
n
.
lau
h
.
kong
l
.
kum
g
.
zeldis
jb
.
knight
r
.
laskin
ol
2007
:
pharmacokinetic
of
lenalidomid
in
subject
with
various
degre
of
renal
impairment
and
in
subject
with
hemodialysis.
j
clin
pharmacol.
47
.
1466
1475.
cheson
bd
.
dutch
bs
2005
:
managing
malignancy
associated
hyperuricemi
with
rasburicase.
j
support
oncol.
3
.
117
124
choueiri
tk
.
alemany
ca
.
abou
jawd
rm
.
budd
gt
2004
:
rol
of
aromatas
inhibitor
in
the
treatment
of
breast
cancer.
clin
ther.
26
.
1199
1214.
curbo
s
.
karlsson
a
2006
:
nelarabine:
a
new
purin
analog
in
the
treatment
of
hematologic
malignancies.
rev
recent
clin
trial
1
.
185
192.
curran
mp
.
croom
kf
.
goa
kl
2004
:
spotlight
on
imatinib
mesylat
in
chronic
myeloid
leukemia.
biodrug
18
.
207
210.
dahl
o
.
lehn
g
.
baksa
.
kvaløy
s
.
christoffers
t
red.
:
medikamentell
kreftbehandling.
cytostatikabok
7.
utg.
2009.
farmakologisk
institutt
.
medisinsk
fakult
.
universitet
oslo.
deining
mw
2008
:
nilotinib.
clin
canc
res.
14
.
4027
4031.
derem
dl
.
ustun
c
.
natarajan
k
2008
:
nilotinib:
a
second
generation
tyrosin
kinas
inhibitor
the
treatment
of
chronic
myelogenous
leukemia.
clin
ter.
30
.
1956
1975.
desoiz
b
.
madoul
c
2002
:
particul
aspect
of
platinum
compound
used
present
in
canc
treatment.
crit
rev
oncol
hematol.
42
.
317
325.
falco
p
.
cavallo
f
.
larocc
a
.
liberati
am
.
musto
p
.
boccadoro
m
.
palumbo
a
2008
:
lenalidomid
and
its
rol
in
the
management
of
multipl
myeloma.
exper
rev
anticanc
ther.
8
.
865
874.
fleming
ra
1997
:
an
overview
of
cyclophosphamid
and
ifosfamid
pharmacology.
pharmacotherapy
17
.
146s
154s.
gebbi
v
.
puozzo
c
2005
:
oral
versus
intravenous
vinorelbine:
clinical
safety
profile.
exper
opin
drug
saf.
4
.
915
928.
gillis
jc
.
goa
kl
1995
:
tretinoin.
a
review
of
its
pharmacodynamic
and
pharmacokinetic
properti
and
use
in
the
management
of
acut
promyelocytic
leukemia.
drug
50
.
897
923.
gwilt
pr
.
tracewell
wg
1998
:
pharmacokinetic
and
pharmacodynamic
of
hydroxyurea.
clin
pharmacokinet.
34
.
347
358.
hartmann
jt
.
lipp
hp
2006
:
camptothecin
and
podophyllotoxin
derivatives:
inhibitor
of
topoisomeras
and
ii
mechanism
of
action
.
pharmacokinetic
and
toxicity
profile.
drug
saf.
29
.
209
230.
hartmann
jt
.
haap
m
.
kopp
hg
.
lipp
hp
2009
:
tyrosin
kinas
inhibitor
a
review
on
pharmacology
.
metabolism
and
sid
effects.
curr
drug
metab.
10
.
470
481.
holt
h
.
smeland
s
.
blystad
ak
.
kvaløy
s
.
hammerstrøm
j
.
tjønnfjord
ge
2002
:
intensiv
kjemoterapi
burkitt
lymfom
aggressiv
non
hodgkin
lymfom.tidsskr
nor
legeforen.
122
.
364
369.
houl
jm
.
clervoix
n
.
bain
s
.
spénard
j
2006
:
lack
of
effect
of
sex
and
diseas
stat
on
the
pharmacokinetic
of
porfim
sodium.
clin
pharmacokin
45
.
923
930.
iss
jpj
.
kantarjian
hm
.
kirkpatrick
p
2005
:
azacitidine.
natur
rev
drug
discovery
4
.
275
276.
jam
ca
.
mant
tg
.
rog
hj
1987
:
pharmacokinetic
of
intravenous
and
oral
sodium
2
mercaptoeth
sulphonat
mesn
in
normal
subjects.
br
j
clin
pharmacol
23
.
561
568.
jon
rj
2008
:
utility
of
dexrazox
the
reduction
of
anthracyclin
induced
cardiotoxicity.
exper
rev
cardiovasc
ther
6
.
1311
1317.
jurlin
jl
.
varco
ar
.
paxton
jw
1985
:
pharmacokinetic
of
amsacrin
in
patient
receiving
combined
chemotherapy
treatment
of
acut
myelogenous
leukemia.
canc
chemoth
pharmacol
14
.
21
25.
kitamur
t
2001
:
necessity
of
re
evaluation
of
estramustin
phosphat
sodium
emp
as
a
treatment
option
first
lin
monotherapy
in
advanced
prostat
cancer.
int
j
urol.
8
.
33
36.
kum
s
.
rajkum
sv
2006
:
thalidomid
and
lenalidomid
in
the
treatment
of
multipl
myeloma.
eur
j
canc
42
.
1612
1622.
lang
sw
2007
:
dexrazox
anthracyclin
extravasation.
exper
rev
anticanc
ther.
7
.
1081
1088.
lober
s
.
puozzo
c
2008
:
pharmacokinetic
.
metabolit
.
and
preclinical
safety
of
vinflunine.
semin
oncol
35
suppl
3
.
s28
s33.
nart
uk
.
kanw
ss
.
azmi
w
2007
:
pharmacological
and
clinical
evaluation
of
l
asparaginas
in
the
treatment
of
leukemia.
crit
rev
oncol
hematol.
61
.
208
221.
petrid
pe
.
gissling
h
.
steur
m
.
linkesch
w
.
krumpl
g
.
schüller
a
.
widmann
r
2009
:
pharmacokinetic
.
bioequivalenc
.
tolerability
.
and
effect
on
platel
count
of
two
formulation
of
anagrelid
in
healthy
volunte
and
patient
with
thrombocythemi
associated
with
chronic
myeloproliferation.
clin
ther.
31
.
386
398.
reck
m
2009
:
gefitinib
in
the
treatment
of
advanced
non
small
cell
lung
cancer.
exper
rev
anticanc
ther.
9
.
401
412.
reign
b
.
blesch
k
.
weidekamm
e
2001
:
clinical
pharmaokinetic
of
capecitabine.
clin
pharmacokinet.
40
.
85
104.
ricciardi
s
.
tomao
a
.
marinis
f
2009
:
toxicity
of
targeted
therapy
in
non
small
cell
lung
canc
management.
clin
lung
canc
10
.
28
35.
sanford
m
.
plosk
gl
2008
:
anastrozole:
a
review
of
its
use
in
postmenopausal
wom
with
early
stag
breast
cancer.
drug
68
.
1319
1340.
sanford
m
.
lyseng
williamson
ka
2008
:
nelarabine.
drug
68
.
439
447.
schteingart
2007
:
adjuvant
mitot
therapy
of
adrenal
canc
use
and
controversy.
n
engl
j
med.
356
.
2415
2418.
schwartz
r
.
davidson
t
2004
:
pharmacology
.
pharmacokinetic
.
and
practical
application
of
bortezomib.
oncology
18
.
14
21.
scriptur
cd
.
sparreboom
a
.
figg
wd
2005
:
modulation
of
cytochrom
p450
activity:
implication
canc
therapy.
lanc
oncol.
6
.
780
789.
siddiqui
maa
.
scott
lj
2005
:
azacitidin
in
myelodysplastic
syndromes.
drug
65
.
1781
1789.
spratlin
j
.
sawy
mb
2007
:
pharmacogenetic
of
paclitaxel
metabolim.
crit
rev
oncol
hematol.
61
.
222
229.
strumberg
d
.
clark
jw
.
awad
a
.
moor
mj
.
richly
h
.
hendlisz
a
.
hirt
hw
.
eder
jp
.
lenz
hj
.
schwartz
b
2007
:
safety
.
pharmacokinetic
.
and
preliminary
antitumor
activity
of
sorafenib:
a
review
of
four
phas
trial
in
patin
with
advanced
refractory
solid
tumors.
oncologist
12
.
426
437.
triesscheijn
m
.
ruevekamp
m
.
out
r
.
van
berkel
tj
.
schell
j
.
baas
p
.
stewart
fa
2007
:
the
pharmacokinetic
behavior
of
the
photosensitiz
meso
tetr
heydroxyphenylchlorin
in
mic
and
men.
canc
chemoth
pharmacol.
60
.
113
122.
van
schaik
rh
2008
:
cyp450
pharmacogenetic
peronalizing
canc
therapy.
drug
resist
updat.
11
.
77
98.
verweij
j
.
pinedo
hm
1990
:
mitomycin
c:
mechanism
of
action
.
usefulness
and
limitations.
anticanc
drug
1
.
5
13.
wilson
j
.
connock
m
.
song
f
.
yao
g
.
fry
smith
a
.
raftery
j
.
peak
d
2005
:
imatinib
the
treatment
of
patient
with
unresectabl
and/or
metastatic
gastrointestinal
stromal
tumours:
systematic
review
and
economic
evaluation.
health
technol
assess.
9
.
1
142.
yun
san
yip
a
.
yen
yen
ong
e
.
chow
lw
2008
:
vinflunine:
clinical
perspectiv
of
an
emerging
anticanc
agent.
exper
opin
invest
drug
17
.
583
591.
preparatomtaler:
www.legemiddelverket.no
.
www.ema.europa.eu
.
www.medicines.org.uk
.
www.medsafe.govt.nz
.
www.axcan.com
azacitidin
siddiqui
maa
.
scott
lj
2005
:
azacitidin
in
myelodysplastic
syndromes.
drug
65
.
1781
1789.
iss
jpj
.
kantarjian
hm
.
kirkpatrick
p
2005
:
azacitidine.
natur
rev
drug
discovery
4
.
275
276.
preparatomtal
vidaz
www.legemiddelverket.no
dasatinib
mcfarland
kl
.
wetzstein
ga
2009
:
chronic
myeloid
leukemi
therapy:
focus
on
second
generation
tyrosin
kinas
inhibitors.
canc
control
16
.
132
140
steinberg
m
2007
:
dasatinib:
a
tyrosin
kinas
inhibitor
the
treatment
of
chronic
myelogenous
leukemi
and
philadelphi
chromosom
positiv
acut
lymphoblastic
leukemia.
clin
ther
29:
2289
2308.
preparatomtal
sprycel
www.legemiddelverket.no
dahl
.
o.
.
lehn
.
g.
.
baksa
.
i.
.
kvaløy
.
s.
christoffers
.
t.
red.
:
medikamentell
kreftbehandling.
cytostatikabok
7.
utg.
farmakologisk
institutt
.
medisinsk
fakult
.
universitet
oslo.
deksrazoksan
lang
sw
2007
:
dexrazox
anthracyclin
extravasation.
exper
rev
anticanc
ther
7:1081
1088.
jon
rj
2008
:
utility
of
dexrazox
the
reduction
of
anthracyclin
induced
cardiotoxicity.
exper
rev
cardiovasc
ther
6
.
1311
1317.
preparatomtal
sav
www.legemiddelverket.no
dahl
.
o.
.
lehn
.
g.
.
baksa
.
i.
.
kvaløy
.
s.
christoffers
.
t.
red.
:
medikamentell
kreftbehandling.
cytostatikabok
7.
utg.
farmakologisk
institutt
.
medisinsk
fakult
.
universitet
oslo.
gefitinib
reck
m
2009
exp
rev
anticanc
ther
9
.
401
402.
hartmann
jt
.
haap
m
.
kopp
hg
.
lipp
hp
2009
curr
drug
metab
10.
470
481.
ricciardi
.
s
.
tomao
a
.
marinis
f
2009
clin
lung
canc
10
.
28
35.
preparatomtal
iress
www.ema.europa.eu
.
dahl
.
o.
.
lehn
.
g.
.
baksa
.
i.
.
kvaløy
.
s.
christoffers
.
t.
red.
:
medikamentell
kreftbehandling.
cytostatikabok
7.
utg.
farmakologisk
institutt
.
medisinsk
fakult
.
universitet
oslo.
klofarabin
bonat
pl
.
arthaud
l
.
cantrell
wr
.
stephenson
k
.
secrist
.
weitman
s
2006
:
discovery
and
development
of
clofarabine:
a
nucleosid
analogu
treating
cancer.
nat
rev
drug
discov
5
.
855
863.
kantarjian
hm
.
jeh
s
.
gandhi
v
.
wess
m
.
faderl
s
2007
:
clofarabine:
past
.
present
.
and
future.
leuk
lymphom
48
.
1922
1930.
robak
t
.
koryck
a
.
lech
marand
e
.
robak
p
2009
:
current
status
of
old
and
new
purin
nucleosid
analogu
in
the
treatment
of
lymphoproliferativ
diseases.
molecul
14
.
1183
1226.
larson
ml
.
venugopal
p
2009
:
clofarabine:
a
new
treatment
option
patient
with
acut
myeloid
leukemia.
exper
opin
pharmacoth
10
.
1353
1357.
preparatomtal
evoltr
www.legemiddelverket.no
lapatinib
medin
pj
.
goodin
s
2008
:
lapatinib:
a
dual
inhibitor
of
human
epidermal
growth
factor
receptor
tyrosin
kinases.
clin
ther
30
.
1426
1447.
ulho
cintr
a
.
greenberg
l
.
geyer
ce
2008
:
the
emerging
rol
of
lapatinib
in
her2
positiv
breast
cancer.
curr
oncol
rep
10
.
10
17.
preparatomtal
atrianc
www.legemiddelverket.no
dahl
.
o.
.
lehn
.
g.
.
baksa
.
i.
.
kvaløy
.
s.
christoffers
.
t.
red.
:
medikamentell
kreftbehandling.
cytostatikabok
7.
utg.
farmakologisk
institutt
.
medisinsk
fakult
.
universitet
oslo.
lenalidomid
kum
s
.
rajkum
sv
2006
:
thalidomid
and
lenalidomid
in
the
treatment
of
multipl
myeloma.
eur
j
canc
42
.
1612
1622.
falco
p
.
cavallo
f
.
larocc
a
.
liberati
am
.
musto
p
.
boccadoro
m
.
palumbo
a
2008
:
lenalidomid
and
its
rol
in
the
management
of
multipl
myeloma.
exper
rev
anticanc
ther
8
.
865
874.
chen
n
.
lau
h
.
kong
l
.
kum
g
.
zeldis
jb
.
knight
r
.
laskin
ol
2007
:
pharmacokinetic
of
lenalidomid
in
subject
with
various
degre
of
renal
impairment
and
in
subject
with
hemodialysis.
j
clin
pharmacol
47
.
1466
1475.
preparatomtal
revlimid
www.legemiddelverket.no
dahl
.
o.
.
lehn
.
g.
.
baksa
.
i.
.
kvaløy
.
s.
christoffers
.
t.
red.
:
medikamentell
kreftbehandling.
cytostatikabok
7.
utg.
farmakologisk
institutt
.
medisinsk
fakult
.
universitet
oslo.
nelarabin
sanford
m
.
lyseng
williamson
ka
2008
:
nelarabin
.
drug
68
.
439
447.
buie
lw
.
epstein
ss
.
lindley
cm
2007
:
nelarabine:
a
novel
purin
antimetabolit
antineoplastic
agent.
clin
ther
29
.
1887
1899.
curbo
s
.
karlsson
a
2006
:
nelarabine:
a
new
purin
analog
in
the
treatment
of
hematologic
malignancies.
rev
recent
clin
trial
1
.
185
192.
preparatomtal
atrianc
www.legemiddelverket.no
.
nilotinib
deining
mw
2008
:
nilotinib.
clin
canc
res
14
.
4027
4031.
derem
dl
.
ustun
c
.
natarajan
k
2008
nilotinib:
a
second
generation
tyrosin
kinas
inhibitor
the
treatment
of
chronic
myelogenous
leukemia.
clin
ter
30
.
1956
1975.
preparatomtal
tasign
www.legemiddelverket.no
.
dahl
.
o.
.
lehn
.
g.
.
baksa
.
i.
.
kvaløy
.
s.
christoffers
.
t.
red.
:
medikamentell
kreftbehandling.
cytostatikabok
7.
utg.
farmakologisk
institutt
.
medisinsk
fakult
.
universitet
oslo.
talidomid
von
lilienfeld
toal
m
.
hahn
ast
c
.
furker
k
.
hoffmann
f
.
naumann
r
.
bargou
r
.
cook
g
.
glasmach
a
2008
:
a
systematic
review
of
phas
ii
trial
of
thalidomide/dexamethason
combination
therapy
in
patient
with
relapsed
or
refractory
multipl
myeloma.
eur
j
haematol
81
.
247
252.
patel
mp
.
chanan
khan
aa
2009
:
the
many
liv
of
thalidomide.
leuk
lymphom
50
.
861
862.
teo
sk
.
colburn
wa
.
tracewell
wg
.
kook
ka
.
stirling
.
jaworsky
ms
.
scheffl
ma
.
thom
sd
.
laskin
ol
2004
:
clinical
pharmacokinetic
of
thalidomide.
clin
pharmacokin
43
.
311
327.
kum
s
.
rajkum
sv
2006
:
thalidomid
and
lenalidomid
in
the
treatment
of
multipl
myeloma.
eur
j
canc
42
.
1612
1622.
sleijf
s
.
kruit
wh
.
stot
g
2004
:
thalidomid
in
solid
tumours:
the
resurrection
of
an
old
drug.eur
j
canc
40
.
2377
2382.
preparatomtal
thalidomid
celgene/pharmion
www.legemiddelverket.no
dahl
.
o.
.
lehn
.
g.
.
baksa
.
i.
.
kvaløy
.
s.
christoffers
.
t.
red.
:
medikamentell
kreftbehandling.
cytostatikabok
7.
utg.
farmakologisk
institutt
.
medisinsk
fakult
.
universitet
oslo.
trabektedin
cart
nj
.
keam
sj
2007
:
trabectedin:
a
review
of
its
use
in
the
management
of
soft
tissu
sarcom
and
ovarian
cancer.
drug
67
.
2257
2276.
preparatomtal
yondelis
www.legemiddelverket.no
dahl
.
o.
.
lehn
.
g.
.
baksa
.
i.
.
kvaløy
.
s.
christoffers
.
t.
red.
:
medikamentell
kreftbehandling.
cytostatikabok
7.
utg.
farmakologisk
institutt
.
medisinsk
fakult
.
universitet
oslo.
vinflunin
bennoun
j
.
delord
jp
.
campon
m
.
nguyen
l:
vinflunine:
a
new
microtubul
inhibitor
agent.
clin
canc
res.
2008
14:
1625
1632.
yun
san
yip
a
.
yuen
yuen
ong
e
.
chow
lw:
vinflunine:
clinical
perspectiv
of
an
emerging
anticanc
agent.
exper
opin
invest
drugs.
2008
.
17:583
591.
lober
s
.
puozzo
c:
pharmacokinetic
.
metabolit
.
and
preclinical
safety
of
vinflunine.
semin
oncol.
2008
.
35
suppl
3
:
s28
33.
preparatomtal
javlor
www.legemiddelverket.no/custom/preparatsok/prepsearch____80333.aspx?searchid=4ea7cff9
c4fc
4188
bce8
71103bc95828
generert:
17.02.2012
forening
utgiv
norsk
legemiddelhåndbok
postboks
63
kalbakk
0901
oslo
http://maps.google.com/maps/place?cid=5501084847365814678
q=sven+oftedals+vei+8
sll=59.925912
.
10.801613
sspn=0.036525
.
0.115218
ie=utf8
ll=59.965151
.
10.745831
spn=0.000086
.
0.000172
t=m
z=13
vpsrc=0
telefon:
22
16
84
90
telefaks:
22
16
84
99
l2.2.htmpost@legemiddelhandboka.no
</body>
</doc>
</tokenized>
